Humira (adalimumab) for rheumatoid arthritis
April 9, 2004 by admin · Leave a Comment
In December of 2002, Abbott Laboratories received FDA approval for Humira®, its human monoclonal antibody for the treatment of adults with moderate to severe rheumatoid arthritis. At that time, Biohorizon placed Humira in its High Impact Technology category and recommended preliminary assessment activites. In an April 2004 company news release, Abbott announced that worldwide sales [...]
Surveillance Summary Feb 7 – Feb 13, 2004
February 13, 2004 by admin · Leave a Comment
Our surveillance program experienced moderate activity throughout week 7 of 2004. A total of 19 technology updates were recorded; 12 of these were new technologies added to our database, while the remaining 7 updates occurred for already existing technology records. Etanercept, Remicade and Visudyne were the only High Impact technologies updated during week 7. Please [...]